Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Genmab A/S stock

Own Genmab A/S stock in just a few minutes.

Genmab A/S is a biotechnology business based in the US. Genmab A/S shares (GMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Genmab A/S employs 781 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Genmab A/S

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GMAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Genmab A/S share price

Use our graph to track the performance of GMAB stocks over time.

Genmab A/S shares at a glance

Information last updated 2021-04-29.
52-week range$24.13 - $44.83
50-day moving average $33.98
200-day moving average $37.16
Wall St. target price$41.57
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $33.19

Buy Genmab A/S shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Genmab A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Genmab A/S under- or over-valued?

Valuing Genmab A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Genmab A/S's PEG ratio

Genmab A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 9.9162. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Genmab A/S's EBITDA

Genmab A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.6 billion.

The EBITDA is a measure of a Genmab A/S's overall financial performance and is widely used to measure a its profitability.

Genmab A/S financials

Revenue TTM $10.1 billion
Operating margin TTM 62.65%
Gross profit TTM $10.1 billion
Return on assets TTM 21.82%
Return on equity TTM 28.69%
Profit margin 47.06%
Book value N/A
Market capitalisation $24.3 billion

TTM: trailing 12 months

Shorting Genmab A/S shares

There are currently 407,961 Genmab A/S shares held short by investors – that's known as Genmab A/S's "short interest". This figure is 13.2% down from 469,981 last month.

There are a few different ways that this level of interest in shorting Genmab A/S shares can be evaluated.

Genmab A/S's "short interest ratio" (SIR)

Genmab A/S's "short interest ratio" (SIR) is the quantity of Genmab A/S shares currently shorted divided by the average quantity of Genmab A/S shares traded daily (recently around 582801.42857143). Genmab A/S's SIR currently stands at 0.7. In other words for every 100,000 Genmab A/S shares traded daily on the market, roughly 700 shares are currently held short.

However Genmab A/S's short interest can also be evaluated against the total number of Genmab A/S shares, or, against the total number of tradable Genmab A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genmab A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Genmab A/S shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Genmab A/S shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genmab A/S.

Find out more about how you can short Genmab A/S stock.

Genmab A/S share dividends

We're not expecting Genmab A/S to pay a dividend over the next 12 months.

Have Genmab A/S's shares ever split?

Genmab A/S's shares were split on a 5:1 basis on 30 April 2018. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab A/S shares which in turn could have impacted Genmab A/S's share price.

Genmab A/S share price volatility

Over the last 12 months, Genmab A/S's shares have ranged in value from as little as $24.13 up to $44.83. A popular way to gauge a stock's volatility is its "beta".

GMAB.US volatility(beta: 0.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab A/S's is 0.5238. This would suggest that Genmab A/S's shares are less volatile than average (for this exchange).

Genmab A/S overview

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site